SANDRA LEONARD — Lobbyist Profile | Poliscope

SANDRA LEONARD

Reported covered position: N/A

Filings

Clients

Firms

Years active

2006–2006

Associated filing income

—

How to read the money

Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.

Clients represented

Client	Filings	Years
ASTRAZENECA PHARMACEUTICALS LP	1	2006

Lobbying firms

Firm	Filings	Years
ASTRAZENECA PHARMACEUTICALS LP	1	2006

Bills explicitly cited in this lobbyist’s assigned issues (6)

No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.

S. 2300

Lower PRICED Drugs Act

Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP

Open original LDA filing ↗

Cited source text

H.R. 5122-Defense Authorization Bill-re price control issues. S.2766-Defense Authorization Bill- re price control issues. Prescription Drug User Fee Act issues. S.3695, Food, Drug, & Cosmetic Act amendments, provisions regarding authorized generic drugs and the 180 day exclusivity period; S.2300,Lower Priced Drug Act, provisions relating to 180 day exclusivity regarding period pediatric studies.

S. 334

Pharmaceutical Market Access and Drug Safety Act of 2005

Client: ASTRAZENECA PHARMACEUTICALS LP · Firm: ASTRAZENECA PHARMACEUTICALS LP

Open original LDA filing ↗

Original LDA source filings (1)

Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.

ASTRAZENECA PHARMACEUTICALS LP via ASTRAZENECA PHARMACEUTICALS LP

2006 · year_end · YY

Firm income: —Client expense: $1,380,000Open original LDA filing ↗

Assigned issues and filing targets (7 issues)

TRD

Trade (domestic/foreign)

H.R. 5337-National Security Foreign Investment Reform Act-re foreign investments in the US.

MED

Medical/Disease Research/Clinical Labs

H.R. 3196-National Institute of Health Reauthorization-re tax breaks for research and development.

CSP

Source: Senate LDA